CA2874065A1 - Procedes et compositions destines a traiter le cancer du sein au moyen de vaccins a cellules dendritiques - Google Patents
Procedes et compositions destines a traiter le cancer du sein au moyen de vaccins a cellules dendritiques Download PDFInfo
- Publication number
- CA2874065A1 CA2874065A1 CA2874065A CA2874065A CA2874065A1 CA 2874065 A1 CA2874065 A1 CA 2874065A1 CA 2874065 A CA2874065 A CA 2874065A CA 2874065 A CA2874065 A CA 2874065A CA 2874065 A1 CA2874065 A1 CA 2874065A1
- Authority
- CA
- Canada
- Prior art keywords
- isolated
- dendritic cells
- cells
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201362002692P | 2013-12-04 | 2013-12-04 | |
| US62/002,692 | 2013-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2874065A1 true CA2874065A1 (fr) | 2015-06-04 |
Family
ID=53365523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2874065A Pending CA2874065A1 (fr) | 2013-12-04 | 2014-12-04 | Procedes et compositions destines a traiter le cancer du sein au moyen de vaccins a cellules dendritiques |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2874065A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019094458A1 (fr) * | 2017-11-07 | 2019-05-16 | Argos Therapeutics, Inc. | Procédés et utilisations pour une thérapie cellulaire dendritique |
| CN115804853A (zh) * | 2021-09-13 | 2023-03-17 | 苏州科锐迈德生物医药科技有限公司 | 包含rna分子的组合物及其在制备瘤内注射剂中的用途 |
| CN116549596A (zh) * | 2023-06-06 | 2023-08-08 | 暨南大学 | 一种长春碱类衍生物在制备治疗淋巴结转移药物中的应用 |
-
2014
- 2014-12-04 CA CA2874065A patent/CA2874065A1/fr active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019094458A1 (fr) * | 2017-11-07 | 2019-05-16 | Argos Therapeutics, Inc. | Procédés et utilisations pour une thérapie cellulaire dendritique |
| US11779599B2 (en) | 2017-11-07 | 2023-10-10 | Coimmune, Inc. | Methods and uses for dendritic cell therapy |
| CN115804853A (zh) * | 2021-09-13 | 2023-03-17 | 苏州科锐迈德生物医药科技有限公司 | 包含rna分子的组合物及其在制备瘤内注射剂中的用途 |
| CN116549596A (zh) * | 2023-06-06 | 2023-08-08 | 暨南大学 | 一种长春碱类衍生物在制备治疗淋巴结转移药物中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10023841B2 (en) | Methods and compositions for treating breast cancer with dendritic cell vaccines | |
| Pai et al. | Clonal deletion of tumor-specific T cells by interferon-γ confers therapeutic resistance to combination immune checkpoint blockade | |
| Westdorp et al. | Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer | |
| Mellman et al. | Cancer immunotherapy comes of age | |
| US20210000953A1 (en) | Use of immune checkpoint inhibitors in central nervous systems neoplasms | |
| Schuler et al. | Phase I dendritic cell p53 peptide vaccine for head and neck cancer | |
| US11945870B2 (en) | Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors | |
| KR20170051462A (ko) | Ｃｄ９４／ｎｋｇ２ａ 및／또는 ｃｄ９４／ｎｋｇ２ｂ 항체, 백신 조합물 | |
| US20090317407A1 (en) | Augmentation of immune response to cancer vaccine | |
| US20180318347A1 (en) | Methods for treating cancer | |
| KR20220005075A (ko) | 키메라 항원 수용체 면역요법의 투여 방법 | |
| Koeneman et al. | Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial | |
| Tijtgat et al. | Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma | |
| CA2874065A1 (fr) | Procedes et compositions destines a traiter le cancer du sein au moyen de vaccins a cellules dendritiques | |
| EP4106775A1 (fr) | Thérapie par lymphocytes t à récepteurs antigéniques chimériques | |
| WO2020232408A1 (fr) | Procédés de traitement | |
| WO2022056491A1 (fr) | Méthodes de traitement | |
| US20250161361A1 (en) | Factors for optimizing immunotherapy efficacy | |
| RU2833461C1 (ru) | Способы лечения рака шейки матки путем введения инибитора pd-1 | |
| Sanmamed et al. | Safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab | |
| US20230061319A1 (en) | Methods of treating tumors | |
| AU2024309282A1 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| EP4608987A1 (fr) | Facteurs d'optimisation de l'immunothérapie | |
| CA3233331A1 (fr) | Anticorps anti-galectine-9 et leurs utilisations therapeutiques | |
| Allison | Checkpoint blockade in tumor immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191113 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241202 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241202 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED Effective date: 20250228 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250228 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250228 |
|
| R15 | Change to inventor requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R15-R108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUEST RECEIVED Effective date: 20250407 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20250627 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251201 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251201 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260325 |
|
| R16 | Change to inventor recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R16-R110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260325 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260325 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260325 |